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Polynucleotide immunisation with the E7 gene of human papillomavirus (HPV) type 16 induces only moderate levels of
immune response, which may in part be due to limitation in E7 gene expression influenced by biased HPV codon usage. Here
we compare for expression and immunogenicity polynucleotide expression plasmids encoding wild-type (pWE7) or synthetic
codon optimised (pHE7) HPV16 E7 DNA. Cos-1 cells transfected with pHE7 expressed higher levels of E7 protein than similar
cells transfected with pW7. C57BL/6 mice and F1 (C57 FVB) E7 transgenic mice immunised intradermally with E7 plasmids
produced high levels of anti-E7 antibody. pHE7 induced a significantly stronger E7-specific cytotoxic T-lymphocyte response
than pWE7 and 100% tumour protection in C57BL/6 mice, but neither vaccine induced CTL in partially E7 tolerant K14E7
transgenic mice. The data indicate that immunogenicity of an E7 polynucleotide vaccine can be enhanced by codonINTRODUCTION
Infection with human papillomavirus (HPV), and partic-
ularly with genotypes 16, 18, 31, or 35, is a major ante-
cedent of anogenital malignancy (Bosch et al., 1995;
Wallin et al., 1999). The E7 protein of HPV16 is expressed
constantly in cervical cancer cells (Seedorf et al., 1987)
and contributes to the transformation and maintenance
of malignant phenotype in epithelial cells in vitro
(Mu¨nger, 1995). Mouse and human T- and B-cell epitopes
of the E7 protein have been identified (Tindle et al., 1990,
1991; Feltkamp et al., 1993; Ressing et al., 1995; Altmann
et al., 1992) and immunity to E7 has been proposed as a
means to prevent or treat HPV-associated cervical ma-
lignancies.
Polynucleotide vaccines can prevent a variety of infec-
tions in animals (Benton and Kennedy, 1998; Donnelly et
al., 1997; Pardoll and Beckerleg, 1995). Immunogenicity
of HPV16 E7 DNA has been demonstrated following
intramuscular or intradermal gene delivery (Chen et al.,
1999; Han et al., 1999; Shi et al., 1999). However, the
cytotoxic T-cell response to E7 polynucleotide vaccines
is not strong (Michel et al., 2002), and several strategies
have been applied to increase the potency of E7 polynu-
cleotide vaccines. These include targeting of antigens
143into antigen processing and presentation pathways by
fusion to genes encoding proteins enhancing protein
spreading between cells (Hung et al., 2001a), ligands for
APC proliferation receptors (Hung et al., 2001c), for anti-
gen receptors on APC (Hung et al., 2001b), for heat shock
protein (Chen et al., 2000b), for lysosomal-associated
membrane protein (Ji et al., 1999), and for proteins with
no obvious immune function (Cheng et al., 2001). Alter-
natively, mutations in E7 which improve expression (Shi
et al., 1999) or prime boost strategies with other antigen
delivery systems (Chen et al., 2000a) have been used.
Recently, the influence of codon usage on the immuno-
genicity of polynucleotide vaccines for viral infection has
been recognised (Andre et al., 1998; Vinner et al., 1999;
Zur Megede et al., 2000; Deml et al., 2001a; Leder et al.,
2001). PV capsid protein expression depends on the
match between codon usage and tRNA availability in
target cells (Zhou et al., 1999), and codon modified
HPV16 L1 and L2 HPV6bL1 and BPV1 L2 polynucleotide
vaccines are more immunogenic than unmodified vac-
cines, when delivered by the gene gun (Liu et al., 2001;
Leder et al., 2001). Here we investigated whether codon
modification can enhance the immunogenicity of an
HPV16 E7 polynucleotide vaccine by examining humoral
and cellular immune responses and host protection
against tumour challenge. We show that polynucleotide
vaccination induces humoral immune responses to E7 inmodification. However, this may be insufficient for prim
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1998) transgenic mice and that codon modification of an
E7 polynucleotide vaccine toward human consensus
codon usage significantly increases E7-specific CTL re-
sponses, but only in the nontransgenic mice.
RESULTS
Codon modified E7 gene significantly increased E7
expression
To compare the expression of codon modified (pHE7)
and wild-type (pWE7) HPV16 E7 genes, Cos-1 cells were
transfected with pWE7 and pHE7. E7 protein was deter-
mined 48 h after transfection by immunofluorescence
and immunoblot, and E7 mRNA was determined by
Northern blot. Data (Fig. 1) are representative of at least
three experiments for each transfection. Of cells trans-
fected with pHE7, 30–40% produced E7 protein within the
cell cytoplasm. Only occasional cells transfected with
pWE7 produced sufficient E7 protein to be recognized by
immunofluorescence (Fig. 1A). E7 was in each case
detected in the cytoplasm of transfected cells, which was
unexpected as E7 is thought to be a nuclear protein
(Greenfield et al., 1991). E7 protein expression was also
assessed by immunoblot analysis. Immunoreactive E7
protein was detected in lysates of cells transfected with
pHE7 but not pWE7 (Fig. 1B). To establish whether the
observed differences in E7 protein expression for pWE7
and pHE7 reflected differing transcription or translation
of the E7 gene, total cellular RNAs were prepared from
Cos-1 cells transfected 48 h previously with the E7 ex-
pression plasmids. Using -actin as an internal stan-
dard, transcription of the codon modified and wild-type
E7 plasmids was quantified and the ratio of E7 mRNA
(pWE7:pHE7), normalised to the -actin internal stan-
dard, was 1:1.3 (Fig. 1C). Higher expression of E7 protein
with the codon modified E7 plasmid was thus a conse-
quence of increased E7 mRNA translation, rather than
increased E7 gene transcription or increased E7 mRNA
stability.
FIG. 1. Expression of E7 protein and of the corresponding mRNA from Wt or codon modified E7 genes. Cos-1 cells were transfected with wt or
modified E7 plasmids. (A) Immunofluorescence analysis of Cos-1 cells transfected by pHE7 and pWE7 with anti-E7 antibodies at 48 h after
transfection. E7 protein was visible in the cytoplasm of cells transfected by pHE7, whereas cells transfected by pWE7 sequences were occasionally
positive (epifluorescence microscopy, original magnification 100). (B) Immunoblot analysis of Cos-1 cell lysates transfected with pWE7 (lanes 1–4)
and pHE7 (lane 5–8) at 48 h after transfection. Lanes 1–4 contain WE7 cellular lysates 10, 2, 0.4, and 0.08 g protein, respectively. Lane 5–8 contain
HE7 cell lysates 10, 2, 0.4, and 0.08g protein, respectively. (I) Coomassie-blue-stained protein gel—markers (M) are 10, 15, 20, 25, 40, 50, 60, 85,
120, and 190 kDa. (II) Immunoblot probed with E7-specific MAb—reactive band is16 kDa. (C) Northern blot analysis of total RNA isolated from Cos-1
cells transfected by pHE7 (lanes 1–3) or pWE7 (lanes 4–6) or mock transfected (lanes 7–9) at 48 h after transfection. Total cellular RNA was extracted
from whole-cell preparations of cells transfected with pWE7 or pHE7. Northern blots were probed with a mixture of 32P-labelled WE7 and HE7
sequences (I) or with -actin probe (II). Lanes 1–3 contain pHE7 total cellular RNA 10, 1, and 0.1 g, respectively. Lanes 3–6 contain pWE7 total cellular
RNA 10, 1, and 0.1 g, respectively, and lanes 7–9 contain normal cellular RNA, 10, 1, and 0.1 g, respectively.
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Increased immunogenicity of HPV16 E7 DNA with
codon modification
To examine in vivo immune responses induced by the
wild-type and codon modified E7 expression vectors,
female C57 BL/6 mice were immunised intradermally
into the abdominal skin using the Helios Gene Gun
(Bio-Rad Laboratories). Two weeks after the second im-
munisation, spleen cells and lymph cells were isolated
from each mouse (four mice per group). To quantify IFN-
secreting E7-specific CD8 T-cell precursor frequencies
generated by E7 DNA vaccines, the ELISPOT assay for
the H-2 Db restricted E7 T-cell epitope RAHYNIVTF was
used. As shown (Fig. 2A), 120 to 160 IFN- spot-forming
T cells specific for RAHYNIVTF were detected per 106
lymphocytes or splenocytes derived from pHE7 immun-
ised mice, compared to 15 to 20 IFN- spot-forming
CD8 T cells/106 splenocytes or lymphocytes from
pWE7 vaccinated mice. No peptide-specific IFN- spot-
forming CD8 T cells were observed in pcDNA3 immun-
ised mice.
CD8 T-cell cytolytic precursors generated by polynu-
cleotide immunisation were determined by standard
chromium release cytolytic assay (Fernando et al.,
1998a). Bulk effector CTL from C57BL/6 mice immunised
by pHE7 DNA vaccine specifically lysed 60–80% of
HPV16 E7 peptide-coated EL4 and E7 transfected tumour
target cells (C2) (Fig. 2B), but did not lyse EL-4 cells in the
absence of E7 peptide, confirming the specificity of the
CTL responses. Bulk effector CTL from C57BL/6 mice
immunised by WE7 DNA vaccine specifically lysed about
20% of HPV16 E7 peptide-coated EL4 and E7 transfected
tumour target cells (C2) (Fig. 2C), compared with no lysis
of these targets by CTL derived from vector DNA immun-
ised mice (Fig. 2D).
Sera from mice immunised with each E7 polynucle-
otide vaccine were tested in ELISA using nine overlap-
ping E7 peptides as substrate (Frazer et al., 1995b).
Peptide-specific antibody was detected in E7 polynucle-
otide vaccinated C57BL/6 mice (Fig. 3) and there was no
statistically significant difference in the response to any
FIG. 2. Assay of E7-specific T cells from C57Bl/6 mice immunised with HPV16 E7 DNA vaccines pWE7 and pHE7. (A) Mice were immunised at days
0 and 14 with codon modified (hE7) or wild-type E7 (wE7) plasmids or with pCDNA3 (pC3) as shown. Splenocytes (S) and lymphocytes (LN) were
harvested on day 24. The number of IFN--producing E7-specific CD8 T-cell precursors was determined using the ELISPOT assay. The spot numbers
were the mean of triplicate determinations  1 SE in each vaccinated group. (B–D) Splenocytes were isolated from mice immunised with codon
modified (B) or wild-type (C) E7 or with control plasmid (D) and were stimulated in vitro with HPV16 E7 peptide (amino acids 49–57). The generated
effector cells were used in standard 51Cr release assays against E7 peptide-coated (EL4-E7) or uncoated (EL4) target cells and against a cell line
expressing endogenous E7 (C2).
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E7 peptide between the pHE7 and pWE7 vaccinated
groups by unpaired t test. E7-specific antibody reactivity
against peptides corresponding to the E7 C terminus
was lower than for peptides corresponding to E7 N-
terminus, as has previously been observed for immuni-
sation with E7 protein (Fernando et al., 1998b).
HPV16 E7 vaccine protected mice against the growth
of TC-1 tumours
We next determined whether E7 polynucleotide im-
munisation could induce protective immunity against
challenge with an HPV16 E7 expressing tumour. C57Bl/6
mice (eight per group) were immunised twice with pHE7
or pWE7 polynucleotide vaccine and challenged subcu-
taneously with 2  106 TC-1 tumour cells 14 days later.
This dose of tumour cells is the minimal dose to induce
tumours in 100% of inoculated mice, based on our pre-
vious experiments. For the pHE7 vaccinated mice, 100%
mice remained tumour-free at 14 and 30 days after the
TC-1 cell challenge, whereas 50% of mice receiving
pWE7 DNA vaccination had developed small tumours by
day 14. Mice receiving a control plasmid each developed
large tumours by 14 days after tumour challenge (Fig. 4).
Codon modified E7 DNA could thus significantly en-
hance E7-specific CTL and induce better immunity
against the growth of TC-1 cells, when compared to
wild-type E7 DNA vaccination.
E7 DNA vaccine induced antibody but not CTL
responses in E7 transgenic mice
Previously, we have shown that specific immunisation
of E7 transgenic mice with E7 protein failed to induce an
E7-specific cellular response or to prevent or control
E7-associated tumour development, in contrast to
non-E7 transgenic control mice (Frazer et al., 1995a).
Immunisation with E7 peptide-pulsed DCs has been re-
ported to overcome E7 directed CTL tolerance (Doan et
al., 2000). Dendritic cells can be directly transfected by
gene-gun-mediated gene delivery. We therefore deter-
mined whether E7 DNA vaccination via a gene gun could
induce a cellular immune response in E7 transgenic
mice. As with C57 BL/6 mice, E7 peptide-specific anti-
body was detected in E7 polynucleotide vaccinated F1
(FVB C57BL/6) mice transgenic for HPV16E7 (Fig. 5A),
confirming previous findings with E7 protein immunisa-
tion that the Th- and B-cell compartments are not
tolerised to E7 in these mice. However, no E7-specific
IFN- secretion by CD8 T cells was detected in ELISPOT
assays following either vaccine (Fig. 5B). These data
suggest that the E7 CTL tolerance in E7 transgenic mice
cannot be overcome by priming of skin-derived DCs.
DISCUSSION
Our data confirm that a polynucleotide vaccine encod-
ing E7 protein can induce an E7-specific CTL response
and some tumour protection in vivo and demonstrate that
the CTL response can be markedly enhanced by codon
modification which results in improved translation of E7
mRNA. As found by others for HIV proteins (Haas et al.,
1996) and ourselves for HPV L1 proteins (Zhou et al.,
1999), altering codon usage in an E7 polynucleotide
vaccine toward mammalian consensus usage results in
better expression of protein in vitro and an improved CTL
response and tumour protection in vivo. After gene gun
immunisation, directly transfected dendritic cells may
prime CD8 cells directly (Porgador et al., 1998) or
CD8 cells may be induced by cross priming (Cho et al.,
2001). The gene transfer procedure results in the activa-
FIG. 4. Tumour weight in mice immunised with control vector (vector)
or HPV16 E7 DNA vaccines WE7 and HE7. Mice were immunised at
days 1 and 14 and at day 24 they were challenged with 2  106 TC-1
cells subcutaneously. The data represent the weight of individual tu-
mours measured at the end of week 2 after tumour challenge. Bars
show the mean tumour weight. The tumour weight from the mice
immunised with HE7 is significantly (P  0.01) less than that from the
mice immunised with WE7.
FIG. 3. E7-specific antibody responses from C57Bl/6 mice immun-
ised with E7 polynucleotide vaccine. Mice (10 per group) were immun-
ised with control vector (vector) or HPV16 E7 DNA vaccines (WE7 and
HE7) via a gene gun. Serum samples were obtained from immunised
mice 14 days after the second vaccination. E7-specific antibody was
detected by nine overlapping 18- to 22-mer peptides, GF101–GF109
(designated 1–9); scanning the length of the E7 protein. ELISA was
carried out using serial dilutions of sera. The results from the 1:100
dilution are presented and show the mean absorbency (OD 490 nm) 
1 SE. Standard errors shown represent variability from mouse to mouse
across the group.
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tion of DCs and initiates migration to regional lymph
nodes, where antigen-expressing DCs efficiently stimu-
late proliferation of antigen-specific CD8 as well as
CD4 T lymphocytes (Tuting et al., 1999). In vivo admin-
istration of DC that have been transfected in vitro is
sufficient to induce both humoral and cellular immune
responses (Doan et al., 2000; Manickan et al., 1997;
Timares et al., 1998). While the most likely explanation for
better immune responses to a polynucleotide vaccine
following codon modification is better protein expres-
sion, as the amount of protein delivered is directly linked
to the magnitude of the induced immune response
(Wherry et al., 1999), it has also been shown that immu-
nostimulatory CpG motifs can stimulate IL-12 release
and hence promote the generation of CTL by polynucle-
otide vaccines (Klinman et al., 1998; Sato et al., 1996).
However, codon modification of the E7 gene did not
increase the number of GACGTT or AACGTT typical CpG
immunostimulatory sequences within the modified gene
(data not shown), and a similar antibody response was
observed to E7 whether the E7 gene was codon modified
or not. Thus, codon modification of E7, which is associ-
ated with higher levels of E7 expression, seems specif-
ically to enhance the CTL response to E7, perhaps be-
cause higher levels of antigen expression are required to
achieve robust T-cell-mediated immunity than a measur-
able antibody response.
The current observation contrasts with recent reports
that codon modification significantly increased antibody
responses for other genes (Andre et al., 1998; Vinner et
al., 1999; Zur Megede et al., 2000; Deml et al., 2001a;
Leder et al., 2001). The mechanism of induction of anti-
body response by polynucleotide vaccines is unclear.
Where intracellular antigens are poorly secreted, as is
the case for E7 protein, induction of antibodies may be
due to the lysis of the expressing cell by the specifically
induced cellular immune response (Griesenbach et al.,
1998). The various early ORFs of PV are nuclear proteins
which induce host protective cell-mediated immunity, but
not a humoral response when administered to rabbits.
Rabbits immunised with CRPV E6-DNA developed E6-
specific cellular immunity as determined by proliferation
assays but did not develop detectable humoral immunity
to E6 proteins, as evaluated by ELISA using two different
E6 antigen preparations (Sundaram et al., 1998). Intra-
muscular injection of plasmid DNA encoding CRPV E1,
E2, E6, or E7 induced CD4 T-cell-mediated but not
humoral immune responses and did not result in the
protection of rabbits from virus infection (Han et al.,
1999). Gene-gun-based intracutaneous vaccination with
a combination of papillomavirus E1 and E2 genes in-
duced strong protective antivirus immunity but not hu-
moral immune response (Han et al., 2000). Previously we
reported that E7 protein degrades very quickly in trans-
fected cells (Park et al., 1993). The results in this paper
were further confirmed by the observation that the codon
optimised E7 protein can be better detected in the pres-
ence of a mixture of proteasome inhibitors. Thus, rapid
intracellular degradation of excess E7 protein might ex-
plain the equal E7 antibody response after pHE7 and
pWE7 DNA vaccination, which presumably reflects the
minimal amount of intact E7 bound by B cells primed by
T helper responses in the draining lymph node and a
need for greater levels of E7 expression for optimal CTL
responses than for optimal antibody response.
The K14E7 transgenic mice (Lambert et al., 1993) ex-
press E7 in the skin and thymus and have been evalu-
ated immunologically as a potential model in which to
test immunotherapy for papillomavirus-associated epi-
thelial cancer. In a previous study, we showed that these
E7 transgenic mice demonstrate split tolerance to E7
protein, in that specific immunisation of E7 transgenic
mice with E7 protein induced antibody and T helper cells
specific for E7 but failed to induce E7-specific cytotoxic T
cell responses sufficient to prevent or control E7-asso-
ciated tumour development (Frazer et al., 1998). It has
been reported that administration of a given peptide in
adjuvant to the immune system may induce tolerance,
FIG. 5. Immune response of K14E7 transgenic mice to immunisation with codon modified or wild-type E7 polynucleotide vaccine. (A) Antibody to
E7 peptides was measured as in Fig. 3. (B) E7-specific CD8 T cells were measured by ELISPOT as for Fig. 2A.
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whereas administration of the same peptide on DCs is
stimulatory (Toes et al., 1998). Peripheral tolerance to
HPV16 E7 oncoprotein can occur by cross-tolerisation,
and immunisation with E7 peptide-pulsed DCs overcame
E7-directed CTL tolerance (Doan et al., 2000). However,
we failed to induce E7-specific CTL responses in K14 E7
F1 (FVB C57 BL/6) E7 transgenic mice via a gene-gun-
mediated polynucleotide vaccination. Why presentation
of E7-specific epitope by peptide-pulsed DCs induces
CTL activation, whereas polynucleotide vaccine primed
skin derived DCs could not induce CTL activation, is
unclear. One explanation might be that only a very small
number of skin-derived DCs were transfected by E7
genes, whereas the previous study used a large number
of peptide-pulsed DCs for immunisation. Alternatively,
polynucleotide vaccination might not activate skin-asso-
ciated LC as effectively as in vitro manipulation of bone-
marrow-derived DC.
Other polynucleotide vaccine strategies have been
used effectively to enhance E7-directed CTLs. The E7
gene, modified so that the open reading frame encoding
mutations in two zinc-binding motifs or mutagenesis of
the pRB-binding site, demonstrated a significant en-
hancement of immunogenicity and better tumour protec-
tion in mice than did a wild-type E7 DNA vaccine (Shi et
al., 1999; Smahel et al., 2001). When administered as a
polynucleotide vaccine, E7 linked to the sorting signal of
the lysosome-associated membrane protein-1 (Sig/E7/
LAMP-1) generated stronger E7-specific CTL activity,
higher numbers of E7-specific CD8 cell precursors,
and higher titres of E7-specific antibody than E7 alone.
Both E7 DNA and Sig/E7/LAMP-1 DNA generated potent
anti-tumour immunity in the liver and lung metastases
models (Chen et al., 1999; Ji et al., 1999), suggesting that
these models require less CTL activity for tumour pro-
tection than the primary tumour model used in the cur-
rent study.
Two nonconservative nucleotide substitutions were
detected in the codon modified E7 gene used in the
current studies. These mutations are probably nonsignif-
icant for protein immunogenicity, as they do not alter any
of the known H-2b restricted T or B epitopes of HPV16 E7
(Altmann et al., 1992; Comerford et al., 1991; Tindle et al.,
1990; Tindle et al., 1991; Feltkamp et al., 1993). The
alteration in the primary DNA sequence might potentially
increase E7 mRNA stability or remove mRNA instability
elements which could increase the E7 mRNA pool and
hence the rate of E7 expression. However, the compa-
rable E7 mRNA levels observed in vitro for the codon
modified and unmodified E7 suggest that this is unlikely.
Alternatively, the amino acid changes resulting from the
two nonconservative nucleotide substitutions might in-
crease the stability of the E7 protein, to account for the
higher steady-state levels of E7 observed in vitro, as
native sequence E7 is known to have short half-life in
vitro and in vivo (Park et al., 1993; Selvey et al., 1994).
However, the enhanced CTL immune response to the
codon modified E7 after delivery as a polynucleotide
vaccine in vivo, when compared with the unmodified E7,
should reflect a larger pool of proteasome degraded E7,
rather than a reduced turnover of E7 as a consequence
of the two amino acid substitutions, as protein modifica-
tions including ubiquitination (Boyle et al., 1998; Tobery
and Siliciano, 1997) which enhance protein degradation
also enhance CTL responses to the modified proteins.
Alternatively, the modifications to the E7 primary se-
quence might alter some of the capacity of E7 to interfere
with its own presentation. However, the mutants ob-
served are not recognised as loss of function mutants in
a protein extensively studied for functional domains, and
expression of the modified E7 protein in vitro results in
cell death, as is observed for wild-type E7 (data not
shown). Thus, codon modification has most likely en-
hanced the efficiency of translation of E7 mRNA, ac-
counting for the increased protein levels observed and
hence increased immunogenicity, as has been observed
for a range of other genes in vitro and in vivo (Deml et al.,
2001b; Koide et al., 2000; Narum et al., 2001; Stratford et
al., 2000; Uchijima et al., 1998).
In conclusion, codon optimisation can enhance the
CTL response induced by E7 polynucleotide vaccination
sufficiently to protect mice against tumour growth. Syn-
thetic genes with optimised codon usage may thus rep-
resent an effective strategy to increase the efficiency of
polynucleotide vaccines targeting tumour antigens.
MATERIALS AND METHODS
Mice and cell lines
Specific pathogen-free female C57BL/6 and F1 (C57
FVB) K14E7 transgenic mice (Herber et al., 1996) aged
6 to 8 weeks were purchased from the Animal Re-
source Centre (Australia) and maintained under clean
conditions in a conventional mouse house. The HPV16
E7 transfected EL4 cell line, C2 (Tindle et al., 1995), and
the parent cell line (EL-4) were maintained in complete
RPMI 1640 medium plus 10% fetal bovine serum (CSL,
Australia).
Construction of codon modified HPV16 E7 DNA
vaccines
The HPV16 E7 gene was modified to substitute mam-
malian preferred codons for rarely used codons (Zhou et
al., 1999). A synthetic E7 gene, incorporating a consen-
sus Kozak sequence and flanked by appropriate restric-
tion enzyme sites, was assembled using overlapping
long synthetic oligonucleotides amplified by PCR. Four
primers were purchased from Life Technologies:













A 5 primer ccgggtaccgccgccaccatgcatggagatacacc-
taca and a 3 primer cgcgaattcttatggtttctgagaacagat
were used to amplify the unmodified E7 gene, incorpo-
rating a Kozak sequence and flanked by restriction sites,
from plasmid pHPV16 (Park et al., 1993). The unmodified
and codon modified E7 genes were cloned into the KpnI
and EcoRI sites of the pcDNA3 mammalian expression
vector (Invitrogen), giving expression plasmids pWE7
and pHE7. Recombinant clones were sequenced to con-
firm the orientation and integrity of the inserted E7 se-
quences. The codon modified recombinant clones dem-
onstrated two point mutations in the primary nucleotide
sequence resulting in a leucine to phenylalanine substi-
tution at aa 28 and a glutamine to arginine substitution at
aa 70.
Immunofluorescence and immunoblot staining
For immunofluorescence staining, Cos-1 cells grown
on eight-well chamber slides were transfected with 0.5
g E7 expression plasmid using lipofectamine (Gibco).
Twenty-four hours after transfection, a mixture of protea-
some inhibitors ALLN (Sigma, 20 g/ml), leupeptin
(Sigma 100 m/ml), and cycloheximide (Sigma, 5 g/ml)
was added and maintained at this concentration for a
further 24 h. Forty-eight hours after transfection, cells
were fixed and permeabilized with 85% ethanol. The
slides were blocked with 5% milk–PBS and probed with
E7-specific monoclonal antibody 6D (Tindle et al., 1990)
followed by fluorescein-isothiocyanate-conjugated anti-
mouse immunoglobulin G (IgG) (Sigma). For immunoblot-
ting assays, cells were harvested 48 h after transfection
and lysed in sodium dodecyl sulphate (SDS) loading
buffer. The cellular proteins were separated by SDS–
polyacrylamide gel electrophoresis in a 10% gel and
blotted onto a nitrocellulose membrane. The membrane
was blocked with 5% skim milk in PBS and probed with
anti-E7 monoclonal antibody at a dilution of 1:2000.
Bound antibody was detected by incubation of the mem-
brane with horseradish-peroxidase-conjugated sheep
anti-mouse antibody (Silenus, Australia) at a dilution of
1:1000 and visualized using enhanced chemilumines-
cence (Amersham).
Northern blotting
Total RNA was extracted from cells transfected 48 h
previously with E7 expression plasmids using lipo-
fectamine (Gibco). Total cellular RNA was separated on a
1.5% agarose gel in the presence of formamide. The
RNAs were blotted onto a nylon membrane and E7
mRNAs were analysed by Northern blot with 32P-labelled
1:1 mixed wt E7 and HE7 cDNA probes and a -actin
cDNA, respectively.
DNA immunisation
Plasmids were purified using a Qiagen Plasmid Mega
kit (Qiagen, Chatsworth, CA) and dissolved in PBS at a
concentration of 1 g/l. Female C57 BL/6 mice and F1
(C57 FVB) E7 transgenic mice, 6 to 8 weeks old, were
immunised by particle bombardment with DNA-coated
gold beads (2 g DNA/dose) using the helium-powered
Helios Gene Gun delivery system (Bio-Rad Laboratories,
Richmond, CA). A total of 1.0 g of DNA was coupled to
0.5 mg of 1.0-m-diameter gold particles, as recom-
mended by the manufacturer. DNA-coated microcarriers
were delivered into the abdominal epidermis at a helium
pressure setting of 400 psi.
Peptide ELISA
Nine peptides 22 amino acids long, overlapping by 12
amino acids, spanning the full length of HPV16 E7 (Frazer
et al., 1995) and synthesized by Chiron (Melbourne,
Australia), were used to determine E7 antibody re-
sponse. Microtiter plates (Dynatech) were coated over-
night with 50 l of different E7 peptide. After being
blocked for 2 h at 37°C with 100 l of 5% milk, 0.05%
Tween 20 in PBS, plates were washed three times with
PBS/0.05% Tween 20. A total of 50 l of sera at dilution
of 1:100 was added for 1 h. Plates were washed again
and 50 l of goat anti-mouse IgG peroxidase conjugate
was added at a 1:5000 dilution. After 1 h, plates were
washed before the addition of OPD substrate. Absor-
bance was measured after 20–30 min at 490 nm in a
Dynatech automated plate reader. As a control, readings
from wells coated with peptide were compared to wells
coated with PBS only.
ELISPOT assay
The ELISPOT assay (Miyahira et al., 1995) was modi-
fied to detect HPV16 E7-specific CD8 T cells. Ninety-
six-well filtration plates (Millipore, Bedford, MA) were
coated with 10 g/ml rat anti-mouse IFN- antibody
(clone R4-6A2, PharMingen, San Diego, CA) in 50 l of
PBS. After overnight incubation at 4°C, the wells were
washed and blocked with culture medium containing
10% fetal bovine serum. A total of 1  106 fresh isolated
spleen and lymph node cells were added to the well
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along with 20 IU/ml IL-2. Cells were incubated at 37°C
for 24 h either with or without 1 g/ml HPV16 E7-specific
H-2Db CTL epitope (RAHYNIVTF, single-letter amino acid
code). After culture, the plate was washed and then
incubated with 5 g/ml biotinylated IFN- antibody
(clone XMG1.2, PharMingen, Franklin Lakes, NJ) in 50 l
in PBS at 4°C overnight. After six washes times, 1.25
g/ml peroxidase (Sigma) in 50 l of PBS was added and
incubated for 2 h at room temperature. After the wash-
ings, spots were developed by the addition of 50 l of
5-bromo-4-chloro-3-3-indolyl phosphate/nitroblue tetra-
zolium solution (Boehringer Manheim, Indianapolis, IN)
and incubated at room temperature for 1 h. The spots
were counted using a dissecting microscope.
In vivo tumour protection
Mice were subcutaneously challenged in the scruff of
the neck with 2  106 cells/mouse of TC-1 tumour cell
(Lin et al., 1996), kindly provided by Dr. T. C. Wu. Tumour
weight was recorded as previously described (Fernando
et al., 1998a). Generally, in groups of mice where tumours
were present at 14 days, all mice were killed and tu-
mours dissected and weighed. Groups of mice without
tumours at 14 days were observed to day 30 for tumour
development.
Cytotoxic T-lymphocyte assays
Splenocytes were prepared from immunised animals
and CTL activity was assessed after a 3-day in vitro
restimulation with rIL-2 (Sigma) and peptide RAHYNIVTF
as previously described (Frazer et al., 1998). Assays were
performed in triplicate, and spontaneous 51Cr release
from the various targets did not exceed 15%.
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